Epidemiology of candidemia in patients with hematologic malignancies and solid tumours in Brazil

Mycoses

Volumn 56, Issue 3, 2013, Pages 256-263

  Bergamasco, M D ^a   Garnica, M ^b   Colombo, A L ^a   Nucci, M ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cancer; Candidemia; Epidemiology; Hematologic malignancy; Mortality; Solid tumour

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; FLUCONAZOLE;

ADOLESCENT; ADULT; AGED; AIR CONDITIONING; ARTICLE; BRAZIL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANDIDEMIA; CENTRAL VENOUS CATHETERIZATION; CHILD; DISEASE SURVEILLANCE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; NEUTROPENIA; PARENTERAL NUTRITION; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SOLID TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BRAZIL; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; FEMALE; HEMATOLOGIC NEOPLASMS; HOSPITAL MORTALITY; HUMANS; INFANT; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84876336398     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12013     Document Type: Article

References (36)

1. Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-9.
2. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-22.
3. Colombo AL, Nucci M, Park BJ et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-23.
4. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
5. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
6. Nakamura T, Takahashi H. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J Infect Chemother 2006; 12: 132-8.
7. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
8. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
9. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493-9.
10. Slavin MA, Sorrell TC, Marriott D et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010; 65: 1042-51.
11. Pasqualotto AC, Rosa DD, Medeiros LR, Severo LC. Candidaemia and cancer: patients are not all the same. BMC Infect Dis 2006; 6: 50.
12. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
13. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-7.
14. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
15. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-8.
16. Grieco A, Long CJ. Investigation of the Karnofsky Performance Status as a measure of quality of life. Health Psychol 1984; 3: 129-42.
17. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts as, 2nd edn. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2002, Document M27-A2.
18. Bodey GP, Mardani M, Hanna HA et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-5.
19. Nucci M, Queiroz-Telles F, Tobon AM, Restrepo A, Colombo AL. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010; 51: 561-70.
20. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010; 67: 162-71.
21. Azevedo AC, Bizerra FC, Matta DA, de Almeida LP, Rosas R, Colombo AL. In vitro susceptibility of a large collection of Candida strains against fluconazole and voriconazole by using the CLSI disk diffusion assay. Mycopathologia 2011; 171: 411-6.
22. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359-66.
23. Playford EG, Marriott D, Nguyen Q et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36: 2034-9.
24. Chen S, Slavin M, Nguyen Q et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12: 1508-16.
25. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005; 41: 975-81.
26. Almirante B, Rodriguez D, Cuenca-Estrella M et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44: 1681-5.
27. Girmenia C, Martino P, De BF et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23: 506-14.
28. Safdar A, Perlin DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002; 44: 11-6.
29. Levin AS, Costa SF, Mussi NS et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998; 30: 243-9.
30. Brito LR, Guimaraes T, Nucci M et al. Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med Mycol 2006; 44: 261-6.
31. Sabino R, Verissimo C, Brandao J et al. Epidemiology of candidemia in oncology patients: a 6-year survey in a Portuguese central hospital. Med Mycol 2010; 48: 346-54.
32. Nucci M, Silveira MI, Spector N et al. Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998; 27: 107-11.
33. Uzun O, Anaissie EJ. Predictors of outcome in cancer patients with candidemia. Ann Oncol 2000; 11: 1517-21.
34. Velasco E, Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008; 27: 1071-8.
35. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-45.
36. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001; 32: 1713-7.